| The immunopeptidomic landscape of ovarian carcinomas H Schuster, JK Peper, HC Bösmüller, K Röhle, L Backert, T Bilich, B Ney, ... Proceedings of the National Academy of Sciences 114 (46), E9942-E9951, 2017 | 170 | 2017 |
| HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy A Marcu, L Bichmann, L Kuchenbecker, DJ Kowalewski, ... Journal for immunotherapy of cancer 9 (4), 2021 | 152 | 2021 |
| Ovarian cyst removal influences ovarian reserve dependent on histology, size and type of operation M Henes, T Engler, FA Taran, S Brucker, K Rall, B Janz, B Lawrenz Women's Health 14, 1745506518778992, 2018 | 52 | 2018 |
| The HLA Ligand Atlas-A resource of natural HLA ligands presented on benign tissues A Marcu, L Bichmann, L Kuchenbecker, DJ Kowalewski, ... BioRxiv, 778944, 2019 | 37 | 2019 |
| A modern approach to endometrial carcinoma: Will molecular classification improve precision medicine in the future? S Marnitz, T Walter, B Schömig-Markiefka, T Engler, S Kommoss, ... Cancers 12 (9), 2577, 2020 | 22 | 2020 |
| Platelet-expressed immune checkpoint regulator GITRL in breast cancer Y Zhou, JS Heitmann, KL Clar, KN Kropp, M Hinterleitner, T Engler, ... Cancer Immunology, Immunotherapy 70 (9), 2483-2496, 2021 | 19 | 2021 |
| Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients–Data from the Real-World Registry PRAEGNANT T Engler, PA Fasching, D Lüftner, AD Hartkopf, V Müller, HC Kolberg, ... Geburtshilfe und Frauenheilkunde 82 (10), 1055-1067, 2022 | 13 | 2022 |
| Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system M Renovanz, SC Kurz, J Rieger, B Walter, H Becker, H Hille, P Bombach, ... Neuro-Oncology Advances 5 (1), vdad012, 2023 | 9 | 2023 |
| Feasibility of adjuvant treatment with abemaciclib—Real-world data from a large German breast center D Dannehl, LL Volmer, M Weiss, S Matovina, EM Grischke, E Oberlechner, ... Journal of Personalized Medicine 12 (3), 382, 2022 | 9 | 2022 |
| Recurrence Score® Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting … D Dannehl, T Engler, LL Volmer, A Staebler, AK Fischer, M Weiss, ... Cancers 14 (21), 5365, 2022 | 8 | 2022 |
| Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse S Mittelstadt, O Kelemen, J Admard, A Gschwind, A Koch, S Wörz, ... British Journal of Cancer 128 (11), 2097-2103, 2023 | 7 | 2023 |
| Characterization and clinical management of abnormal cytology findings in pregnant women: a retrospective analysis R Freudenreich, M Weiss, T Engler, F Neis, M Henes Archives of Gynecology and Obstetrics 306 (6), 2017-2026, 2022 | 7 | 2022 |
| Design of interactive augmented reality functions for robotic surgery and evaluation in dry‐lab lymphadenectomy MP Forte, R Gourishetti, B Javot, T Engler, ED Gomez, KJ Kuchenbecker The International Journal of Medical Robotics and Computer Assisted Surgery …, 2022 | 7 | 2022 |
| Neoadjuvant chemotherapy of patients with early breast cancer is associated with increased detection of disseminated tumor cells in the bone marrow L Volmer, A Koch, S Matovina, D Dannehl, M Weiss, G Welker, M Hahn, ... Cancers 14 (3), 635, 2022 | 7 | 2022 |
| .(2021) HLA ligand atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy A Marcu, L Bichmann, L Kuchenbecker, DJ Kowalewski, ... J. Immunother. Cancer 9, e002071, 0 | 6 | |
| Measuring the time to deterioration for health-related quality of life in patients with metastatic breast cancer using a web-based monitoring application: longitudinal cohort study K Brusniak, M Feisst, L Sebesteny, A Hartkopf, J Graf, T Engler, ... JMIR cancer 7 (4), e25776, 2021 | 5 | 2021 |
| The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers H Schäffler, F Mergel, K Pfister, S Lukac, A Fink, K Veselinovic, B Rack, ... International Journal of Molecular Sciences 24 (22), 16366, 2023 | 4 | 2023 |
| Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers D Dannehl, T Engler, LL Volmer, CM Tegeler, J Fusshoeller, E Gabrysch, ... Cancers 15 (15), 3847, 2023 | 4 | 2023 |
| Implementation of an electronic patient-reported outcome app for health-related quality of life in breast cancer patients: evaluation and acceptability analysis in a two-center … J Graf, N Sickenberger, K Brusniak, LM Matthies, TM Deutsch, E Simoes, ... Journal of Medical Internet Research 24 (2), e16128, 2022 | 4 | 2022 |
| Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer P Kaidun, SJ Holzmayer, SM Greiner, A Seller, CM Tegeler, I Hagelstein, ... International Journal of Molecular Sciences 24 (17), 13156, 2023 | 2 | 2023 |
